Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome.

Buzzelli V, Carbone E, Manduca A, Schiavi S, Feo A, Perederiy JV, Ambert KH, Hausman M, Trezza V

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (0)

No references identified in the available metadata. This does not establish that none exist.

    Cited by — these papers cite this paper (5)

    1. Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortex 2026-07-28 · Expand citations
    2. Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review 2026-07-01 · Expand citations
    3. Company on brink takes psilocybin to trial for fragile X syndrome 2023-01-01 · Expand citations
    4. Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses 2023-01-01 · Expand citations
    5. Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data 2023-01-01 · Expand citations